Many ADHD Medications Lead to Increases in Blood Pressure and Heart Rate
By Elana Gotkine HealthDay Reporter
MONDAY, April 21, 2025 -- Many pharmacological treatments for attention-deficit/hyperactivity disorder (ADHD) lead to increases in hemodynamic signs, including blood pressure and pulse, according to a review published in the May issue of The Lancet Psychiatry.
Luis C. Farhat, Ph.D., from the Universidade de São Paulo in Brazil, and colleagues compared the effects of pharmacological treatments for ADHD on hemodynamic signs and electrocardiographic parameters in children, adolescents, and adults. Published and unpublished randomized controlled trials (RCTs) comparing amphetamines, atomoxetine, bupropion, clonidine, guanfacine, lisdexamfetamine, methylphenidate, modafinil, or viloxazine -- either against each other or against placebo -- were identified; 101 RCTs with short-term follow-up were included, encompassing 22,257 participants.
The researchers found that in children and adolescents, adults, or both, amphetamines, atomoxetine, lisdexamfetamine, methylphenidate, and viloxazine led to increases in hemodynamic signs. Among children and adolescents, the mean increase against placebo varied from 1.07 mm Hg with atomoxetine to 1.81 mm Hg with methylphenidate for systolic blood pressure; from 1.93 mm Hg with amphetamines to 2.42 mm Hg with methylphenidate for diastolic blood pressure; and from 2.79 beats per minute (bpm) with viloxazine to 5.58 bpm with atomoxetine for pulse. Among adults, the mean increase against placebo ranged from 1.66 mm Hg with methylphenidate to 2.3 mm Hg with amphetamines for systolic blood pressure; from 1.6 mm Hg with methylphenidate to 3.07 mm Hg with lisdexamfetamine for diastolic blood pressure; and from 4.37 bpm with methylphenidate to 5.8 bpm with viloxazine for pulse. In children and adolescents, and in adults, guanfacine was associated with decrements in hemodynamic signs.
"Our findings confirmed that amphetamines, atomoxetine, lisdexamfetamine, methylphenidate, and viloxazine may lead to short-term increments in heart rate, blood pressure, or both in children and adolescents, adults, or both age groups," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2025
Read this next
Hypertension Deaths From Excessive Alcohol Use Are Increasing
THURSDAY, July 3, 2025 -- The estimated mean annual number of hypertension deaths from excessive alcohol use was higher in 2020-2021 than in 2016-2017, with a higher increase...
ADHD Medications Remain Linked to Lower Risk for Real-World Adverse Outcomes
WEDNESDAY, July 2, 2025 -- Attention-deficit/hyperactivity disorder (ADHD) medications remain associated with a reduced risk for various real-world outcomes, but the magnitude of...
Onset of Sepsis in First Week of Life Tied to Increased Likelihood of Autism Spectrum Disorder
TUESDAY, June 24, 2025 -- Early-onset neonatal sepsis is associated with increased likelihood autism spectrum disorder (ASD) and of attention-deficit/hyperactivity disorder...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.